BridGene Biosciences, Inc.

Founded in 2018 and based in San Jose, US, BridGene Biosciences is a biotech firm focusing on the discovery and development of innovative small molecules targeting undruggable proteins associated with various diseases. BridGene Biosciences specializes in drug discovery and development, utilizing its proprietary Chemoproteomics platform, IMTAC™. In October 2025, BridGene Biosciences, Inc. raised USD 28 million in series B funding led by new investor Bayland Capital, with participation from other new investors GTJA Investment Group and Proxima Ventures.

Returning investors Lapam Capital and Grains Valley Venture Capital also participated in the round. The round was part of a larger USD 66. 5 million series B funding. BridGene Biosciences primarily specializes in the discovery and development of innovative small molecules aimed at targeting high-value yet previously undruggable proteins associated with various diseases.

The company's flagship offering is its proprietary Chemoproteomics platform, known as IMTAC™ (Isobaric Mass Tagged Affinity Characterization), which facilitates the screening of small molecules against the entire proteome of live cells. This technology enables the identification of drug candidates for challenging targets, such as oncogenic mutations, that are difficult to address with traditional therapies. BridGene's products are intended for pharmaceutical companies and research institutions globally, particularly in key markets such as North America, Europe, and Asia, where there is a growing demand for novel therapeutic solutions in precision medicine. BridGene Biosciences generates revenue through strategic partnerships and collaborations primarily with large pharmaceutical companies, such as Takeda.

These partnerships often include upfront payments for access to BridGene's IMTAC™ technology, as well as milestone payments tied to the progression of specific drug discovery programs. For example, BridGene is eligible to receive substantial milestone payments as each collaboration achieves clinical and commercial milestones. The revenue model is structured around B2B transactions, where BridGene provides its proprietary technology and expertise in drug discovery to pharmaceutical partners, creating a stream of income through licensing agreements and potential royalties from future drug sales derived from these collaborations. The specific financial details of these arrangements are generally not disclosed publicly, reflecting the proprietary nature of the agreements.

The company will use the October 2025 funding to advance its lead drug BGC-515 into Phase 2 trials, support a second program entering the clinic in 2027, and expand its platform for oncology and autoimmune research.